帕博利珠单抗在晚期程序性死亡配体1阳性子宫内膜癌中的安全性与抗肿瘤活性:KEYNOTE-028研究结果
多队列Ib期KEYNOTE-028研究评估帕博利珠单抗在程序性死亡配体1(PD-L1)阳性晚期实体瘤中的安全性与疗效,本文报告晚期子宫内膜癌队列结果。24例经标准治疗进展的PD-L1阳性晚期子宫内膜癌患者接受帕博利珠单抗10 mg/kg每2周治疗,客观缓解率为13.0%(95%CI 2.8%至33.6%),安全性可控。
要点
- 24例可评估患者中3例(13.0%)确认部分缓解,中位缓解持续时间未达到。
- 3例(13.0%)疾病稳定,中位持续时间24.6周。
- 13例(54.2%)发生治疗相关不良事件,4例为3级,无4级不良事件及因不良事件停药。
核心结论
- 帕博利珠单抗在经多线治疗的晚期PD-L1阳性子宫内膜癌患者亚组中显示出良好的安全性特征和持久的抗肿瘤活性。
研究设计与样本
- 多队列Ib期KEYNOTE-028研究(NCT02054806),评估帕博利珠单抗在PD-L1阳性晚期实体瘤患者中的安全性和疗效,本文报告晚期子宫内膜癌队列。
主要发现
- 筛查75例患者,36例(48.0%)为PD-L1阳性肿瘤,24例(32.0%)入组。
- 24例入组患者中15例(62.5%)既往接受过至少两线晚期疾病治疗。
- 3例(13.0%)达到确认的部分缓解(95%CI 2.8%至33.6%),中位缓解持续时间未达到;截至数据截止时2例仍在治疗并持续缓解。
- 3例(13.0%)达到疾病稳定,中位持续时间24.6周。
- 13例(54.2%)发生治疗相关不良事件,≥10%的不良事件包括疲乏(20.8%)、瘙痒(16.7%)、发热(12.5%)和食欲下降(12.5%);4例报告3级治疗相关不良事件,无4级不良事件,无患者因不良事件停止治疗。
关键数值与推荐
- 给药方案:帕博利珠单抗10 mg/kg每2周一次,最长24个月或直至疾病进展或不可接受的毒性。
- 主要疗效终点:按RECIST版本1.1评估的客观缓解率;次要终点包括安全性、缓解持续时间、无进展生存期和总生存期。
- 数据截止日期:2016年2月17日。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose The multicohort phase Ib KEYNOTE-028 (NCT02054806) study was designed to evaluate the safety and efficacy of pembrolizumab, an anti-programmed death 1 monoclonal antibody, in patients with programmed death ligand 1 (PD-L1) -positive advanced solid tumors. The results from the advanced endometrial cancer cohort are reported. Patients and Methods Female patients with locally advanced or metastatic PD-L1-positive endometrial cancer who had experienced progression after standard therapy were eligible. Patients received pembrolizumab 10 mg/kg every 2 weeks for up to 24 months or until progression or unacceptable toxicity. Primary efficacy end point was objective response rate by RECIST (version 1.1). Secondary end points included safety, duration of response (DOR), progression-free survival, and overall survival. The data cutoff was February 17, 2016. Results Of 75 patients screened, 36 (48.0%) had PD-L1-positive tumors, and 24 (32.0%) were enrolled. Fifteen (62.5%) of these 24 patients had received at least two previous lines of therapy for advanced disease. Three patients (13.0%) achieved confirmed partial response (95% CI, 2.8% to 33.6%); the median DOR was not reached. Two patients were still receiving treatment and exhibiting continued response at time of data cutoff. Three additional patients (13.0%) achieved stable disease, with a median duration of 24.6 weeks. One patient who achieved partial response had a polymerase E mutation. Thirteen patients (54.2%) experienced treatment-related adverse events (AEs), with fatigue (20.8%), pruritus (16.7%), pyrexia (12.5%), and decreased appetite (12.5%) occurring in ≥ 10% of patients. Grade 3 treatment-related AEs were reported in four patients. No patient experienced a grade 4 AE, and no patient discontinued treatment because of an AE. Conclusion Pembrolizumab demonstrated a favorable safety profile and durable antitumor activity in a subgroup of patients with heavily pretreated advanced PD-L1-positive endometrial cancer.
引用
- Ott PA, Bang YJ, Berton-Rigaud D, et al. Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive Endometrial Cancer: Results From the KEYNOTE-028 Study. J Clin Oncol. 2017. PMID: 28489510. doi:10.1200/JCO.2017.72.5952
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。